Peter A. Bampton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peter A. Bampton has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Jane M. Andrews
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
18 shared publications - Graeme Paul Young
College of Medicine and Public Health, Flinders Health and Medical Research Institute Flinders University Adelaide South Australia Australia
10 shared publications - Miles Patrick Sparrow
Alfred Health and Monash University
8 shared publications Ruth Prosser
8 shared publications- Sally Bell
St Vincent's Hospital, Melbourne, VIC
7 shared publications - Gillian Mahy
Department of Gastroenterology, Townsville Hospital, Townsville, Australia
6 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (1) , e00452
Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
INTRODUCTION: Dipeptidyl peptidase (DPP)-4 is part of a larger family of proteases referred to as DPPs. DPP4 has been suggested as a possible biomarker for inflammatory bowel disease (IBD). Circulating DPP4 (cDPP4) enzyme activity was investigated as a potential biomarker for IBD. In addition, DPP enzyme activity and gene expression were quantified in colonic tissue of patients with IBD and non-IBD. METHODS: In study 1, DPP enzyme activity was quantified in plasma samples from 220 patients with IBD (Crohn's disease [CD] n = 130 and ulcerative colitis [UC] n = 90) and non-IBD controls (n = 26) using a colorimetric assay. In study 2, tissue and plasma samples were collected from 26 patients with IBD and 20 non-IBD controls. Plasma C-reactive protein (CRP) was quantified in all patients. Colonic DPP4, DPP8, DPP9, and fibroblast activation protein (FAP) gene expression was determined by quantitative polymerase chain reaction. cDPP and cFAP enzyme activity was also measured. Sensitivity and specificity were determined by receiver operating characteristic curve analysis. RESULTS: In study 1, total cDPP activity was found to differentiate patients with CD with active disease (n = 18) from those in remission (n = 19; sensitivity 78% and specificity 63%). In study 2, total cDPP and cFAP activity was 28% and 48% lower in patients with elevated CRP (>10 mg/L), respectively, compared with patients with normal CRP. Gene expression of DPP4, FAP, and DPP8 was also significantly higher in colonic biopsies from patients with IBD compared with non-IBD patients (P < 0.05). DISCUSSION: Our findings implicate the DPP enzyme family in intestinal inflammation and suggest future biomarker applications to differentiate the pathophysiological aspects of IBD.
- 1 January 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (1) , e00452
Open AccessCirculating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
INTRODUCTION: Dipeptidyl peptidase (DPP)-4 is part of a larger family of proteases referred to as DPPs. DPP4 has been suggested as a possible biomarker for inflammatory bowel disease (IBD). Circulating DPP4 (cDPP4) enzyme activity was investigated as a potential biomarker for IBD. In addition, DPP enzyme activity and gene expression were quantified in colonic tissue of patients with IBD and non-IBD. METHODS: In study 1, DPP enzyme activity was quantified in plasma samples from 220 patients with IBD (Crohn's disease [CD] n = 130 and ulcerative colitis [UC] n = 90) and non-IBD controls (n = 26) using a colorimetric assay. In study 2, tissue and plasma samples were collected from 26 patients with IBD and 20 non-IBD controls. Plasma C-reactive protein (CRP) was quantified in all patients. Colonic DPP4, DPP8, DPP9, and fibroblast activation protein (FAP) gene expression was determined by quantitative polymerase chain reaction. cDPP and cFAP enzyme activity was also measured. Sensitivity and specificity were determined by receiver operating characteristic curve analysis. RESULTS: In study 1, total cDPP activity was found to differentiate patients with CD with active disease (n = 18) from those in remission (n = 19; sensitivity 78% and specificity 63%). In study 2, total cDPP and cFAP activity was 28% and 48% lower in patients with elevated CRP (>10 mg/L), respectively, compared with patients with normal CRP. Gene expression of DPP4, FAP, and DPP8 was also significantly higher in colonic biopsies from patients with IBD compared with non-IBD patients (P < 0.05). DISCUSSION: Our findings implicate the DPP enzyme family in intestinal inflammation and suggest future biomarker applications to differentiate the pathophysiological aspects of IBD.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1746 - The Clinical Utility of Interval Fecal Immunochemical Testing During Colonoscopic Surveillance in an Above Average Risk Population
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1746 - The Clinical Utility of Interval Fecal Immunochemical Testing During Colonoscopic Surveillance in an Above Average Risk Population
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- Open Access
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Open AccessPerformance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S576
UV Exposure and Skin Type are More Important than Thiopurine Exposure for Non-Melanoma Skin Cancer Risk in IBD
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S576
UV Exposure and Skin Type are More Important than Thiopurine Exposure for Non-Melanoma Skin Cancer Risk in IBD
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S546
A Nurse-Led Model Increases Concordance with Recall Guidelines within a Colorectal Cancer Surveillance Program
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S546
A Nurse-Led Model Increases Concordance with Recall Guidelines within a Colorectal Cancer Surveillance Program
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S948
Tu1792 Expression of Gut Homing Markers on TReg Differs Between IBS and Remissive IBD
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S948
Tu1792 Expression of Gut Homing Markers on TReg Differs Between IBS and Remissive IBD